Literature DB >> 20151197

Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites.

Renaud Schoemans1, Marie-Stéphane Aigrot, Chaohong Wu, Raphaël Marée, Pengyu Hong, Shibeshi Belachew, Claire Josse, Catherine Lubetzki, Vincent Bours.   

Abstract

Phenylketonuria (PKU) is a metabolic genetic disease characterized by deficient phenylalanine hydroxylase (PAH) enzymatic activity. Brain hypomyelination has been reported in untreated patients, but its mechanism remains unclear. We therefore investigated the influence of phenylalanine (Phe), phenylpyruvate (PP), and phenylacetate (PA) on oligodendrocytes. We first showed in a mouse model of PKU that the number of oligodendrocytes is not different in corpus callosum sections from adult mutants or from control brains. Then, using enriched oligodendroglial cultures, we detected no cytotoxic effect of high concentrations of Phe, PP, or PA. Finally, we analyzed the impact of Phe, PP, and PA on the myelination process in myelinating cocultures using both an in vitro index of myelination, based on activation of the myelin basic protein (MBP) promoter, and the direct quantification of myelin sheaths by both optical measurement and a bioinformatics method. None of these parameters was affected by the increased levels of Phe or its derivatives. Taken together, our data demonstrate that high levels of Phe, such as in PKU, are unlikely to directly induce brain hypomyelination, suggesting involvement of alternative mechanisms in this myelination defect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151197      PMCID: PMC3071566          DOI: 10.1007/s10545-010-9052-3

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  38 in total

1.  Comments on the neuropathology of phenylketonuria.

Authors:  C A Dyer
Journal:  Eur J Pediatr       Date:  2000-10       Impact factor: 3.183

2.  Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis?

Authors:  C Demerens; B Stankoff; B Zalc; C Lubetzki
Journal:  Neurology       Date:  1999-01-15       Impact factor: 9.910

3.  Evidence for central nervous system glial cell plasticity in phenylketonuria.

Authors:  C A Dyer; A Kendler; T Philibotte; P Gardiner; J Cruz; H L Levy
Journal:  J Neuropathol Exp Neurol       Date:  1996-07       Impact factor: 3.685

4.  Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?

Authors:  S Shefer; G S Tint; D Jean-Guillaume; E Daikhin; A Kendler; L B Nguyen; M Yudkoff; C A Dyer
Journal:  J Neurosci Res       Date:  2000-09-01       Impact factor: 4.164

5.  Characterization of mutations at the mouse phenylalanine hydroxylase locus.

Authors:  J D McDonald; C K Charlton
Journal:  Genomics       Date:  1997-02-01       Impact factor: 5.736

6.  Phenylalanine reduces synaptic density in mixed cortical cultures from mice.

Authors:  Friederike Hörster; Marina A Schwab; Sven W Sauer; Joachim Pietz; Georg F Hoffmann; Jürgen G Okun; Stefan Kölker; Stefan Kins
Journal:  Pediatr Res       Date:  2006-04       Impact factor: 3.756

7.  Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis.

Authors:  Marieke Hoeksma; Dirk-Jan Reijngoud; Jan Pruim; Harold W de Valk; Anne M J Paans; Francjan J van Spronsen
Journal:  Mol Genet Metab       Date:  2009-02-06       Impact factor: 4.797

Review 8.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

9.  Phenylketonuria: genotype-phenotype correlations based on expression analysis of structural and functional mutations in PAH.

Authors:  Angel L Pey; Lourdes R Desviat; Alejandra Gámez; Magdalena Ugarte; Belén Pérez
Journal:  Hum Mutat       Date:  2003-04       Impact factor: 4.878

10.  Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

Authors:  R Matalon; K Michals-Matalon; G Bhatia; A B Burlina; A P Burlina; C Braga; L Fiori; M Giovannini; E Grechanina; P Novikov; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2007-02-27       Impact factor: 4.750

View more
  6 in total

Review 1.  Oxidative stress in phenylketonuria-evidence from human studies and animal models, and possible implications for redox signaling.

Authors:  Vanessa Trindade Bortoluzzi; Carlos Severo Dutra Filho; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2021-02-13       Impact factor: 3.584

2.  Automatic robust neurite detection and morphological analysis of neuronal cell cultures in high-content screening.

Authors:  Chaohong Wu; Joost Schulte; Katharine J Sepp; J Troy Littleton; Pengyu Hong
Journal:  Neuroinformatics       Date:  2010-06

Review 3.  Genetic etiology and clinical challenges of phenylketonuria.

Authors:  Nasser A Elhawary; Imad A AlJahdali; Iman S Abumansour; Ezzeldin N Elhawary; Nagwa Gaboon; Mohammed Dandini; Abdulelah Madkhali; Wafaa Alosaimi; Abdulmajeed Alzahrani; Fawzia Aljohani; Ehab M Melibary; Osama A Kensara
Journal:  Hum Genomics       Date:  2022-07-19       Impact factor: 6.481

Review 4.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

Review 5.  Engineering Organoids for in vitro Modeling of Phenylketonuria.

Authors:  Alice C Borges; Kerensa Broersen; Paula Leandro; Tiago G Fernandes
Journal:  Front Mol Neurosci       Date:  2022-01-10       Impact factor: 5.639

6.  High phenylalanine concentrations induce demyelination and microglial activation in mouse cerebellar organotypic slices.

Authors:  Orli Thau-Zuchman; Patrick N Pallier; Paul J M Savelkoul; Almar A M Kuipers; J Martin Verkuyl; Adina T Michael-Titus
Journal:  Front Neurosci       Date:  2022-09-29       Impact factor: 5.152

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.